Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio

By The Northwire Desk — AI Analysis Dec 08, 2025 · 08:30 AIAI · 1.06 NetraMark Holdings Inc.
AIAI · Price

Executive Summary

  • NetraMark Holdings announced that its peer‑reviewed paper on the NetraAI platform has been accepted for publication in npj Digital Medicine (Nature Portfolio).
  • The study demonstrates how NetraAI can identify interpretable patient subpopulations (“Personas”/MDS) to improve precision enrichment in a Phase II ketamine trial for treatment‑resistant depression.
  • Company executives highlighted the significance of explainable AI for regulatory science and clinical‑trial design.

Key Details

  • Publication: “Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial,” accepted by npj Digital Medicine.
  • Data Source: National Institute of Mental Health (NIMH) Phase II ketamine trial in treatment‑resistant depression.
  • Key Findings: NetraAI uncovered interpretable “Personas” that may guide precision‑enrichment strategies across psychiatry and other therapeutic areas; integration of dynamical‑systems modeling, long‑range‑memory feature learning, and LLM explainability improves decision‑making and reduces placebo interference.
  • Co‑authors: Researchers from NIMH (Dr. Elizabeth D. Ballard, Dr. Carlos A. Zarate Jr.) plus NetraMark scientists and academic collaborators.
  • Executive Comments:
  • Dr. Joseph Geraci (Chief Scientific & Technical Officer) – emphasized the paper’s role in validating the AI engine for clinical trials.
  • Dr. Luca Pani (Chief Innovation & Regulatory Officer) – noted the importance of explainability, reproducibility, and traceability for regulators and investigators.
  • Access: Full article available at https://www.nature.com/articles/s41746-025-02143-7.

Notable Quotes

“Acceptance of this paper for publication by npj Digital Medicine affirms the progress we’ve made toward building an AI engine purpose‑built for clinical trials.” – Dr. Joseph Geraci, CSO & CTO

“This publication bridges scientific innovation with the rigorous expectations of regulatory science…provides regulators and clinical investigators with credible tools designed to support modern clinical trial design and decision‑making.” – Dr. Luca Pani, Chief Innovation and Regulatory Officer

Read the original news release →

More from NetraMark Holdings Inc.

Jun 29, 2026 · 07:00

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

M&A / Property May 14, 2026 · 17:00

NetraMark Secures Capital Runway Amidst Slow Revenue Conversion and Backlog Growth

Other May 05, 2026 · 10:40

NetraMark TSX Listing Confirms Exchange Status But Price Divergence Signals Skepticism Over Revenue Conversion

Regulatory Apr 22, 2026 · 07:00

NetraMark Capitalizes on Psychedelic Regulatory Tailwinds Amidst Price Consolidation

Production / Operations Apr 20, 2026 · 07:00

NetraMark Commentary on Psychedelic Executive Order Fails to Halt Downtrend Despite Insider Buying

Regulatory Apr 09, 2026 · 07:00

NetraMark’s quantum‑brain paper adds scientific cache but no immediate financial upside

Other